Single‐Arm Clinical Trials as Pivotal Evidence for Cancer Drug Approval: A Retrospective Cohort Study of Centralized European Marketing Authorizations Between 2010 and 2019-Reference-Cited by-同舟云学术

Single‐Arm Clinical Trials as Pivotal Evidence for Cancer Drug Approval: A Retrospective Cohort Study of Centralized European Marketing Authorizations Between 2010 and 2019

Published:2020-08-19 Issue:3 Volume:108 Page:653-660
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin. Pharmacol. Ther.

Author:

Tenhunen Olli¹²,Lasch Florian³,Schiel Anja⁴,Turpeinen Miia¹^ORCID

Affiliation:

1. Medical Research Center Oulu Oulu University Hospital University of Oulu Oulu Finland

2. Finnish Medicines Agency Helsinki Finland

3. Hannover Medical School Hannover Germany

4. Norwegian Medicines Agency Oslo Norway

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpt.1965

Reference20 articles.

1. Seamless designs: current practice and considerations for early‐phase drug development in oncology;Hobbs B.P.;J. Natl. Cancer Inst.,2019

2. Seamless Oncology-Drug Development

3. European Medicines Agency (EMA).Guideline on the evaluation of anticancer medicinal products in man.. Accessed February 18 2020.

4. Personalized medicine in oncology: the future is now

5. Basket Trials and the Evolution of Clinical Trial Design in an Era of Genomic Medicine

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Justifying the source of external comparators in single-arm oncology health technology submissions: a review of NICE and PBAC assessments;Journal of Comparative Effectiveness Research;2024-02

2. Unanchored Population-Adjusted Indirect Comparison Methods for Time-to-Event Outcomes Using Inverse Odds Weighting, Regression Adjustment, and Doubly Robust Methods With Either Individual Patient or Aggregate Data;Value in Health;2023-12

3. Review time of oncology drugs and its underlying factors: an exploration in China;Frontiers in Pharmacology;2023-11-01

4. Representation of older patients in the safety analysis of protein kinase inhibitor registration studies;Journal of Geriatric Oncology;2023-11

5. Indirect treatment comparison of brexucabtagene autoleucel (ZUMA-2) versus standard of care (SCHOLAR-2) in relapsed/refractory mantle cell lymphoma;Leukemia & Lymphoma;2023-10-16